Overview / Abstract: |
Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions. |
Expiration |
Aug 27, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
.50 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Oguz Akin, MD Robert Motzer, MD Elizabeth Plimack, MD, MS Jay Raman, MD, FACS |
Activity Specialities / Related Topics |
Oncology / Cancer / Radiation Therapy, Nephrology, Radiology / Imagery / Nuclear Medicine, Surgery, Urology |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent medical education grants from Exelixis, Inc., and Merck & Co., Inc.. |
Keywords / Search Terms |
ACHL CME/CE, CME, CE, Akin, Motzer, Raman, Plimack, Penn State, RCC, ccRCC, renal cell carcinoma, patient case, oncology, radiology, imaging, virtual tumor board, tumor board, lesion, CARMENA, sunitinib, nephrectomy, NCCN, histology, CheckMate 214, KEYNOTE-426, CheckMate 9ER, surgery Free CE CME |